The article entitled "Comparison of Lepirudin and Argatroban Outcomes" by Smythe and colleagues in this issue of the journal is of particular interest because it presents the only data available on the comparison of these direct thrombin inhibitors (DTIS) for the treatment of heparininduced thrombocytopenia (HIT) in terms of certain efficacy and safety parameters in a contemporary setting outside of a clinical trial. This retrospective analysis of clinical practices in the post-marketing period of January 2000 to December 2001 reflects the manner in which these two drugs were being used for the treatment of HIT at one American hospital. The efficacy parameters analyzed were the effectiveness of anticoagulation in terms of achieving a therapeutic activated partial thromboplastin time ratio (APTT ratio), the time required to achieve it, and the fraction of time that a therapeutic level was maintained. The frequency of dosage adjustments up or down for each drug was analyzed as well. The comparative safety of each drug was determined from the percentage of major bleeds in each group.
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Efficacy results in terms of the parameters measured were remarkably similar for these drugs, with the exception of the time to achieve a therapeutic APTT ratio, which was shorter for argatroban, 6.0 ± 5.3 hours vs 11.2 ± 11.6 hours for lepirudin (p = 0.04). The percentage of patients requiring dose titration was marginally higher in the lepirudin group (82.5% vs 63.0% in the argatroban group.)
The incidence of major bleeding was relatively high in both groups, lepirudin 11.5% and argatroban 10.3%. Minor bleeding was 37.7% for lepirudin and 27.6% for argatroban (difference not significant).
Recent major critical reviews (1,2) have pointed out that without well-designed head-to-head clinical trials, it is not possible to state which of these two DTI drugs is the most efficacious and safe for the treatment of HIT, and this includes the cases without new thrombosis during heparin therapy (non-thrombotic HIT) as well as those with new thrombosis during heparin therapy (HITT). We completely agree with this position, and do not imply that this paper by Smythe and colleagues satisfies the criteria that would be required for such a trial. Clinical outcomes in terms of new thromboembolic events, amputations, and death are essential parts of such trials. In point of fact, the relative proportions of patients with HIT vs. HITT in each group in this study were not stated. In this study a new diagnosis of HIT was the indication for the argatroban therapy in 44.8% of the patients treated with that drug,whereas it was the indication for lepirudin in 57.4% of the patients treated with that drug.
The mean initial dose of lepirudin was 0.08 ± 0.05 mg/kg/hr. The argatroban group was treated at a mean initial rate of 1.09 ± 0.62 mcg/kg/min by infusion. At these dosages, the APTT ratios were therapeutic within a mean of 11.2 hours for lepirudin and 6.0 hours for argatroban, a significant difference (p = 0.04). How this translated into clinical outcome in terms of new thrombosis, amputation, and death, and the composite outcome were not reported because the number of subjects with newly diagnosed HIT in each treatment group were too few for statistical comparison. There were 61 patients in the lepirudin group and 29 in the argatroban group. No reason for the difference is stated. That argatroban was not approved for clinical use until the year this study started (2000) may have accounted for the difference in the number in each group. The data do show that argatroban was used relatively more frequently in the patients with renal disease, reflecting the fact that renal impairment mandates lowering the dose of lepirudin to accommodate its longer half-life in such patients. 1 In spite of its limitations in not providing clinical outcomes data on clinical end points of new thromboses, amputations, and death or their composite, it does reflect clinical practice in terms of dosage regimens for HIT and the efficiency with which therapeutic levels in terms of APTT ratios are achieved. In the HAT trials of lepirudin therapy for HIT/HITT the achievement of a therapeutic APTT ratio was "immediate," but those patients were given an initial bolus of 0.4 mg/kg before starting an infusion of 0.15 mg/kg/hr until a therapeutic APTT ratio was achieved (3, 4) . The FDA-approved dosing for lepirudin is the same as that used in the HAT trials, which included dose reductions for patients with impaired renal function (3) (4) (5) . There have been recent publications that support the concept that lepirudin may be given at a lower dosage in patients with "isolated HIT." In 2004, Lubenow and colleagues reported a subset of patients with "isolated HIT" gleaned from previous prospective multicenter trials of lepirudin (3) (4) (5) . Patients who had venous or arterial thrombosis less than 20 days before the clinical diagnosis of HIT were compared with a separately analyzed group who had HIT with no thrombosis within the previous 20 days. In these studies lepirudin was given as an intravenous infusion of 0.10 mg/kg/hr with no bolus. Infusion rates were adjusted to reach 1.5-to 2.5-fold prolongation of the patient's baseline APTT value or the mean of the laboratory normal range. To be entered into the trial, patients had to have a decrease in platelet counts of 30% or more or to 100,000/microliter or less, and a positive laboratory test result for HIT. During an observation period of 24 days, a composite end point of 19.8% was observed in the group that had no thromboemboli within the previous 20 days. It is of considerable interest that an analysis of the subgroup that had venous or arterial thrombosis within 20 days of entry into the trial, revealed that 13.3% had new thromboemboli (TECs), whereas there were only 1.1% in the "isolated" HIT group. There was a combined end point of 33.3% in the recent TEC group contrasted with 19.8% in the "isolated HIT group" (5) . From this it is clear that patients who are being treated with heparin for a thrombosis of recent onset (<20 days) cannot be safely treated with this particular lepirudin regimen because it is ineffective in such patients. They should be treated with an initial bolus unless there is a clinical reason not to do so.
It is reasonable to expect better outcomes when the DTIs are started promptly after the diagnoses is suspected and at a dosage recommended in the package insert by the pharmaceutical company, or in the Physicians Desk Reference (PDR) in the United States (6) . Alternatively there are current recommendations published as a consensus statement in the journal Chest 2004 (supplement) (7) .
The clinical trials of lepirudin required that results of the HIT test be positive before the patient was entered into the trial (3, 4) . Because heparin was stopped when the clinical diagnosis was suspected, there would have been a delay while the serum sample was transported to the central laboratory (often at another hospital). There was another delay while waiting for the results of the test and a further delay of 1.7 days before the drug was started (day 1 of the study). There was at least a 50% to 75% chance that new thrombi were forming in the HIT patients between the time of cessation of the heparin and the achievement of a therapeutic APPT ratio with lepirudin (1, 7) . The extent to which new thrombi appeared during this window of delay in the lepirudin studies is not known but since an analysis showed a rate of 6.1%/day for new thromboses during the 1.7-day delay between a positive test result and the start of lepirudin therapy, new thrombi were occurring on a daily basis (1) (2) (3) (4) . A confounding factor in the lepirudin studies is the fact that some patients had been on heparin therapy, others on a combination of heparin and LMWH and danaparoid, and others were on danaparoid alone (3). It has since been concluded that lepirudin (and argatroban) must be started as soon as HIT is strongly suspected and heparin or low molecular weight heparin (LMWH) therapy is stopped (7) .
Smythe and associates compared these two drugs as much as possible without having a head-to-head clinical trial to determine efficacy and safety. A critical aspect of a head-to-head trial would be to define the criteria necessary for making the diagnosis of "high probability" HIT and proceeding with cessation of heparin or LMWH. Strong recommendations for starting the drug, for dosing adjustments, and for the transition to oral anti-coagulants are important. Because HIT has been shown to have a 50% to 75% probability of an occult new thrombosis during heparin therapy it seems logical that HIT and HITT should be treated with the same regimen for either diagnosis, as is the recommendation for argatroban therapy. The special subset of "isolated HIT" who have had no thromboses within the previous 20 days may be treated without a bolus of lepirudin and with an infusion of 0.10 mg/kg/hr (target 1.5-2.5 APTT ratio) as recommended in the seventh ACCP consensus conference (7) . Many of the differences observed when comparing trials with historical controls are not solely due to the efficacy of the drug in interrupting the hypercoagulable state, but also to the timing of the first dose and the time required to achieve therapeutic anti-coagulation. The fact that oral anti-coagulants were, as a rule, started much earlier following the clinical diagnosis of HIT, and possibly at higher doses, could be a cause for a higher composite end point in historical controls. This could make the study drug look better in comparison to the historical controls. When comparing lepirudin trials with argatroban trials, it is tempting to speculate upon the differences in outcomes based upon nuances of the trial protocols, but it remains impossible to arrive at definite conclusions.
Certain principles are critically important in the treatment of these patients: (a) early decision to stop heparin, (b) immediate initiation of DTIs treatment, (c) cautious introduction of oral anti-coagulants (OAC) at a time when it is safe, and (d) timely discontinuance of the combined therapy as soon as it is determined that the international normalized ratio is therapeutic. The need for an overlap time of 4 to 5 days has not been clearly established for the DTIs and warfarin in combination (as was shown to be necessary with heparin, which has little ability to inhibit clot bound thrombin in contrast to argatroban and lepirudin) (8, 9) , but it certainly is necessary to overlap these drugs for at least 3 to 4 days with any drug because of the time needed for prothrombin to decay to low levels. The inhibition of clot bound thrombin (which is more effective with argatroban than with lepirudin) may permit shorter duration of the overlap time, but the recommendation is that OACs not be started until platelets are well on their way to recovery and the two drugs should overlap by 4 to 5 days (7) .
It is axiomatic that achievement of a therapeutic APTT rapidly is more important than following dosing protocol, but as a rule the protocol leads to a therapeutic APTT ratio in an effective and safe manner.
